Apparently, tackling Cytoken in AIRDS is an issue and CYK have the capacity to address it but stay their course.
Meanwhile MSB with the same capacity power on.
Not sure with this stock.
Arrogantly stick with the plan or provide a common good?
Opportuniy knocks.
Hopelessly inopportunic
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.010(5.56%) |
Mkt cap ! $34.32M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 19.5¢ | 18.0¢ | $9.062K | 48.88K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 104632 | 18.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 3 | 1 |
View Market Depth
| Last trade - 14.37pm 12/09/2024 (20 minute delay) ? |
| CYP (ASX) Chart |